Update on treatment regimens: Prophylaxis versus on-demand therapy

Seminars in Hematology

Volumn 40, Issue 3 SUPPL. 3, 2003, Pages 3-9

  Manco Johnson, Marilyn J ^a,b  

^a Children's Hospital Colorado   (United States)

^b MS F416 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHROPATHY; BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HISTORY OF MEDICINE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VASCULAR ACCESS;

EID: 79952657396     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)80732-1     Document Type: Article

References (31)

1. Arnold WD, Hilgartner MW: Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 59A:287-305, 1977
2. Manco-Johnson MJ, Nuss R, Geraghty S, et al: Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 47:113-117, 1994
3. Nilsson IM, Berntorp E, Lofqvist T, et al: Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232:25-32, 1992
4. National Hemophilia Foundation: MASAC Recommendations #117: MASAC recommendation concerning prophylaxis (prophylactic administration of clotting factor concentrate to prevent bleeding) (revised June 9, 2001). Washington, DC, National Hemophilia Foundation. Available at: http://www.hemophilia.org/programs/masac/masac/masac117.htm. Accessed February 12, 2003
5. Blanchette VS, McCready M, Achonu C, et al: A survey of prophylaxis in boys with hemophilia followed in North American hemophilia treatment centers. Haemophilia 9:19-26, 2003 (suppl)
6. Johnson JB: The management of hemophilia with lyophile human plasma intravenously injected. JAMA 118:799-802, 1942
7. Ahlberg A: Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand 77:3-132, 1965 (suppl)
8. Robinson PM, Tittley P, Smiley RK: Prophylactic therapy in classical hemophilia: A preliminary report. Can Med Assoc J 97:559, 1967
9. Shanbrom E, Thelin GM: Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. JAMA 208:1853-1856, 1969
10. Van Creveld S: Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 41:206-214, 1969
11. Hirschman RJ, Itscoitz SB, Shulman NR: Prophylactic treatment of factor VIII deficiency. Blood 35:189-194, 1970
12. Aledort LM, Haschmeyer RH, Pettersson H, et al: A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 236:391-399, 1994
13. Onwuzurike N, Warrier I, Lusher JM: Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia 2:137-140, 1996
14. Petrini P: How to start prophylaxis. Haemophilia 9:83-87, 2003 (suppl)
15. He S, Bremme K, Blomback M: A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 96:145-156, 1999
16. Al Dieri R, Peyvandi F, Santagostino E, et al: The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 88:576-582, 2002
17. Butenas S, Mann KG: Blood coagulation. Biochemistry (Mosc) 67:3-12, 2002
18. Fijnvandraat K, Peters M, ten Cate JW: Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 91:474-476, 1995
19. Broze GJ, Higuchi DA: Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88:3815-3823, 1996
20. Mosnier LO, Lisman T, van den Berg HM, et al: The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 86:1035-1039, 2001
21. Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381-1389, 2002
22. Nichols WC, Amano K, Cacheris PM, et al: Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 88:1183-1187, 1996
23. Ettingshausen CE, Halimeh S, Kurnik K, et al: Symptomatic onset of severe hemophilia A in childlhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 85:218-220, 2001
24. Tizzano EF, Soria JM, Coll I, et al: The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 87:279-285, 2002
25. Gilbert MS: Prophylaxis: Musculoskeletal evaluation. Semin Hematol 30:3-6, 1993
26. Manco-Johnson MJ, Nuss R, Funk S, et al: Joint evaluation instruments for children and adults with haemophilia. Haemophilia 6:649-657, 2000
27. Pettersson H: Modern radiologic evaluation and follow up of hemophilia, in Wiedel J, Gilbert M (eds): Management of Musculoskeletal Problems in Hemophilia. New York, NY, The National Hemophilia Foundation, 1986, pp 7-12
28. Nuss R, Kilcoyne RF, Geraghty S, et al: MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 6:162-169, 2000
29. Bullinger M, Von Mackensen S, Fischer K, et al: Pilot testing of the 'Haemo-QoL' quality of life questionnaire for haemophilic children in six European countries. Haemophilia 8:47-54, 2002
30. Manco-Johnson MJ, Blanchette VS: North American studies for persons with severe hemophilia: Background, rationale and design. Haemophilia 9:44-49, 2003 (suppl)
31. Hacker MR, Geraghty S, Manco-Johnson MJ: Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 7:392-396, 2001